Rituximab Therapy for Insulin Allergy in Type-1 Diabetes Mellitus

Area of Science:

• Immunology
• Endocrinology
• Dermatology

Background:

• Insulin allergy, though reduced with human insulin, still affects up to 2.4% of patients.
• Rituximab, a CD20-targeting monoclonal antibody, is used for lymphoproliferative and rheumatological conditions.
• Limited reports suggest rituximab's potential in severe, refractory insulin allergy.

Observation:

• A 40-year-old woman with T1DM developed severe, refractory insulin allergy.
• Symptoms included painful skin reactions, panniculitis, and lipodystrophy.
• Conventional treatments (antihistamines, glucocorticoids, insulin changes) were ineffective.

Findings:

• Rituximab infusion was administered as an investigational treatment.
• The patient achieved prolonged remission of her insulin allergy.
• Skin biopsy confirmed sublobular panniculitis.

Implications:

• Rituximab represents a viable immunotherapy option for severe insulin allergy unresponsive to standard care.
• Clinicians should consider rituximab for refractory insulin allergy cases.
• This case highlights rituximab's efficacy in a challenging clinical scenario.